What is PRE's current stock price?

PRE (Prenetics Global Limited) is currently trading at $17.21 with a market cap of $292.5M.

What sector is Prenetics Global Limited in?

Prenetics Global Limited (PRE) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

Is PRE a good stock to buy?

Analysts have a Buy consensus on PRE with a price target of $36.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PRE Prenetics Global Limited

Healthcare

$17.20+0.00%OpenMarket Cap: $292.5M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.54

P/S

3.00

EV/EBITDA

-6.22

DCF Value

$-1,259.54

FCF Yield

-7.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

53.0%

Operating Margin

-41.3%

Net Margin

-61.3%

ROE

-36.0%

ROA

-28.7%

ROIC

-22.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$36.6M	$-28.1M	$—
FY null	$92.4M	$-37.7M	$—
Q3 null	$23.6M	$-7.4M	$—
Q2 null	$17.7M	$-12.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$36.00

Target (Median)

$36.00

Target Range

$36.00 - $36.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Cantor FitzgeraldOverweight

2025-10-29

Trading Activity

Insider Trades

View All

Lo Hoi Chunofficer: Chief Financial Officer

SellWed May 20

Yeung Danny Sheng Wudirector, officer: Chief Executive Officer

SellMon Mar 30

Yeung Danny Sheng Wudirector, officer: Chief Executive Officer

SellMon Mar 30

Shah Darshan Ravindradirector

SellMon Mar 30

Shah Darshan Ravindradirector

SellMon Mar 30

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

0.15

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Peers